NCT04508725Completed
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Early Therapeutic Monitoring of Response to Therapy With Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Source: ClinicalTrials.gov · Last updated 25 Jul 2025
Brief summary (registry, in English)
To assess whether changes in quantitative tumor perfusion parameters after 3 or 6 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 22 (actual)
- First submitted
- 29 Jul 2020
- Start date
- 5 Dec 2020
- Primary completion date
- 30 Nov 2023
- Lead sponsor
- Stanford University
- Diseases
- Kidney cancer
- NCT number
- NCT04508725
What you commit to
- Study type: Interventional
- Participants enrolled: 22
- From 5 Dec 2020 to the primary completion date, 30 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- -Any comorbid condition that, in the opinion of the treating provider or the Protocol Directors, compromises the participant's ability to participate in the study
Who the study is looking for
- 18 years of age or older
- Pathology-confirmed diagnosis of Renal cell carcinoma (RCC)
- At least one tumor lesion greater than 1 cm in diameter, amenable to ultrasound imaging
- Written informed consent.
- Specific inclusion criteria:
- Arm 1: planned to be treated with combination of VEGFR2 tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)
- Arm 2: planned to be treated with non-ICI therapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stanford University School of Medicine Coordinator of this site? Confirm its status | Stanford | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.